Cysteamine is the first chemical identified that induces acute and chronic duodenal ulcers in rodents. Structure-activity studies with cysteamine, propionitrile and their derivatives, as well as with analogues of toluene, revealed numerous alkyl and aryl duodenal ulcerogens. Among these, one of the most interesting from an etiologic and pathogenetic point of view is the dopaminergic neurotoxin MPTP, which shows structural similarities with toluene. The chemically-induced duodenal ulcers are similar and localized on the anterior and posterior wall of the duodenal bulb. Both cysteamine and MPTP affect endogenous dopamine; MPTP is especially potent in depleting central dopamine and inducing lesions in the substantia nigra. MPTP given in high doses induces Parkinson's disease-like syndrome and gastric ulcers. Cysteamine and propionitrile also cause dyskinesia in large and multiple doses. The motility disorders and duodenal ulcers are abolished by dopamine agonists. Cysteamine and MPTP have been known to increase and decrease gastric acid secretion, respectively. However, both compounds induced duodenal dysmotility, decreased bicarbonate production, and reduced its delivery from distal to proximal duodenum. These factors decrease acid neutralization in the duodenal bulb and contribute to duodenal ulceration. Thus, studies with animal models may reveal endogenous mediators and specific receptors which might be involved in the pathogenesis of duodenal ulceration. Specific structure-activity studies in toxicology may lead to new insights in the pathogenesis and pharmacology of a poorly understood human disorder such as duodenal ulceration.
References
1.
1. Brooks FP (1985). The pathophysiology of peptic ulcer disease.Dig. Dis. Sci.30: 15S–29S.
2.
2. Fields JZ, Dali H, Neumeyer J, and Szabo S (1986). Duodenal ulcers induced by MPTP may be caused by nigrostriatal lesion. In: MPTP: A Neurotoxin Producing a Parkinsonian Syndrome, SP Markey, N Castagnoli Jr, AJ Trevor, and IJ Kopin (eds). Academic Press, New York, pp. 385–389.
3.
3. Gallagher GT and Szabo S (1984). Secretory changes associated with chemically-induced duodenal ulceration: Simultaneous measurements of acid, pepsin, base and pancreatic enzymes in rats with chronic gastric fistural.Digestion29: 73–84.
4.
4. Giampaolo C, Poulsen SS, Szabo S, Reynolds ES, and Feldman D (1978). Stereomicroscopic and ultrastructural characterization of propionitrile-induced duodenal ulcer in the rat.Lab. Invest.38: 1–7.
5.
5. Guth PH, Aures S, and Poulsen G (1979). Topical aspirin plus HC1 gastric lesions in the rat. Cytoprotective effect of prostaglandin, cimetidine and probanthine.Gastroenterology77: 88–93.
6.
6. Horner HC and Szabo S (1980). Central and peripheral dopamine and noradrenaline in the pathogenesis of cysteamine-induced duodenal ulcer disease.Gastroenterology78: 1183.
7.
7. Irwin I and Langston JW (1985). Selective accumulation of MPP+ in the substantia nigra: A key to neurotoxicity.Life Sci.36: 207–212.
8.
8. Konturek SJ (1984). Control and regulation of duodenal acidity. In: Mechanisms of Mucosal Protection in the Upper Gastrointestinal Tract, A Allen, G Flemstrom, A Garner, W Silen, and LA Turnberg (eds). Raven Press, New York, pp. 159–165.
9.
9. Lichtenberger LM, Szabo S, and Trier JS (1977). Duodenal ulcerogens cysteamine and propionitrile stimulate serum gastrin levels in the rat.Gastroenterology73: 1305–1308.
10.
10. Mangla J, Pihan G, Brown HM, Rattan S, and Szabo S (1985). Duodenal ulcerogens cysteamine, mepirazole and MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) change duodenal myoelectric activity in the rat.Gastroenterology88: 1488.
11.
11. Marshall F and Szabo S (1987). Correlation between ulcerogenic and neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its reduced derivative in rats.Gastroenterology92: 2062.
12.
12. Neumeyer JL and Szabo S (1983). (–)–10–11-Methylenedioxy-n-propyl-noraporphine, an orally effective dopamine agonist and duodenal antiulcerogen in the rat.Eur. J. Pharmacol.33: 273–274.
13.
13. Peters TJ, Sharp G, Stiel D, and Wilkes J (1984). Biochemical basis of bicarbonate secretion by rat duodenal mucosa. In: Mechanisms of Mucosal Protection in the Upper Gastrointestinal Tract, A Allen, G Flemstrom, A Garner, and W Silen (eds). Raven Press, New York, pp. 181–187.
14.
14. Pfeiffer DC, Pfeiffer CJ, and Szabo S (1987). Development of cysteamine-induced ultrastructural surface changes on duodenal mucosa.Lab. Invest.56: 444–450.
15.
15. Pihan G, Kline TJ, Hollenberg NK, and Szabo S (1985). Duodenal ulcerogens cysteamine and propionitrile induced gastroduodenal motility alterations in the rat.Gastroenterology88: 989–997.
16.
16. Pihan G, Gallagher GT, and Szabo S (1985). Biliary and pancreatic secretions influence experimental duodenal ulcer without affecting gastric secretion in the rat.Dig. Dis. Sci.30: 240–246.
17.
17. Poulsen SS and Szabo S (1977). Mucosal surface morphology and histological changes in the duodenum of the rat following the administration of cysteamine.Br. J. Exp. Pathol.58: 1–8.
18.
18. Poulsen SS, Olsen PS, and Kirkegaard P (1985). Healing of cysteamine-induced duodenal ulcers in the rat.Dig. Dis. Sci.30: 161–167.
19.
19. Raghaven P (1962). Epidemiology and clinical behavior of peptic ulcer in Bombay, India.Gastroenterology42: 130–143.
20.
20. Schulz I (1981). Electrolyte and fluid secretion in the exocrine pancreas. In: Physiology of the Gastrointestinal Tract, LR Johnson, J Christensen, ED Jacobson, MI Grossman, and SG Schulta (eds). Raven Press, New York, pp. 159–165.
21.
21. Selye H (1936). A syndrome produced by diverse nocuous agents.Nature138: 32.
22.
22. Selye H (1973). Production of perforating duodenal ulcers by 3,4-toluenediamine in the rat.Proc. Soc. Exp. Biol. Med.142: 1192–1196.
23.
23. Selye H (1976). Stress in Health and Disease.Butterworth, Boston, Massachusetts.
24.
24. Selye H and Szabo S (1973). Experimental mode for production of perforating duodenal ulcers by cysteamine in the rat.Nature (London)244: 458–459.
25.
25. Szabo S (1979). Dopamine disorder in duodenal ulceration.Lancetii: 880–882.
26.
26. Szabo S (1984). Biology of disease. Pathogenesis of duodenal ulcer disease.Lab. Invest.51: 121–147.
27.
27. Szabo S and Gallagher GT (1980). Acute and chronic duodenal ulcers produced by cysteamine or n-butyronitrile in the rat. In: Advances in Experimental Ulcer, S Umehara and H Ito (eds). 4th International Conference on Experimental Ulcer, Tokyo, Japan, pp. 116–128.
28.
28. Szabo S and Gallagher GT (1984). Effects of alkyl nitriles on the gastrointestinal tract.Surv. Synth. Pathol. Res.3: 11–30.
29.
29. Szabo S and Pihan G (1987). Development and significance of cysteamine and propionitrile models of duodenal ulcer.Chronobiol. Int.4: 31–41.
30.
30. Szabo S and Reichlin S (1981). Somatostatin in rat tissues is depleted by cysteamine administration.Endocrinology109: 2255–2257.
31.
31. Szabo S and Reichlin S (1985). Somatostatin depletion by cysteamine: Mechanism and implication for duodenal ulceration.Fed. Proc.44: 2540–2545.
32.
32. Szabo S and Reynolds ES (1975). Structure-activity relationships for ulcerogenic and adrenocorticolytic effects of alkyl nitriles, amines and thiols.Environ. Health Perspect.11: 135–140.
33.
33. Szabo S and Selye H (1972). Duodenal ulcers produced by propionitrile in rats.Arch. Pathol.93: 390–392.
34.
34. Szabo S, Brown A, Pihan G, Dali H, and Neumeyer JL (1985). Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).Proc. Soc. Exp. Biol. Med.180: 567–571.
35.
35. Szabo S, Horner HC, and Gallagher GT (1982). Drug-induced duodenal ulcer: Structure-activity correlations and pathogenesis. In: Drugs and Peptic Ulcer, Vol. 2, CJ Pfeiffer (ed). CRC Press, Boca Raton, Florida, pp. 53–74.
36.
36. Szabo S, Pihan S, Gallagher GT, and Brown A (1984). Role of local secretory and motility changes in the pathogenesis of experimental duodenal ulcer.Scand. J. Gastroenterol. (Suppl. 92) 19: 106–111.
37.
37. Szabo S, Reynolds E, and Unger SH (1982). Structure-activity relations between alkyl nucleophilic chemicals causing duodenal ulcer and adrenocortical necrosis.J. Pharmacol. Exp. Therap.223: 68–76.
38.
38. Whittle BJR (1977). Mechanisms underlying gastric mucosal damage by indomethacin and bile salts and the actions of prostaglandins.Br. J. Pharmacol.60: 455–460.
39.
39. Ziering H, Berger L, Heineinan SD, and Lee J (1947). Piperidine derivatives: 4 Aryl piperidines.J. Org. Chem.12: 894–903.
